CHAMPIX helps quit smoking with prescription drugs

Pfizer has announced that the National Institute of Clinical Practice (NICE) has recommended Champix to the National Centre forHealthfor use by adults who want to quit smokingThis provides an important treatment option for smokers across England, Wales and Northern Ireland to help them quit smokingIn its final assessment, the UK's National Institute of Clinical Practice concluded that varenicline was more effective in achieving sustainable smoking cessation than nicotine replacement therapy (NRT) and bupropion, and that its use in smoking cessation "would make it more likely that the UK's NationalHealthCentre would save costs."" The decision means that smokers who are committed to quitting are given another option in a series of smoking cessation treatments that have been proven in a number of clinical trialsRobert West, professor of
psychologypsychology at the University of London, saidSmokers who combine treatment with appropriate complementary measures, such as access to smoking cessation services, will significantly increase their chances of quitting throughout life"
, Champix is the first new prescription drug to help quit smoking in the last decadeBy targeting its unique mechanisms of regulating nicotine-specific receptors, Pfizer has discovered and developed Champix, which is designed to help quit smokingChampix can work by reducing the desire of smokers to smoke In clinical trials, the rate of discontinuation of treatment for adverse reactions was similar to that of placebo, and patients generally had a good tolerance to varenicline The most common side effects include nausea, headaches, sleep disturbances, and changes in dreams Smoking is the world's leading preventable cause of death and the cause of the world's 5 million lives lost each year The World Health Organization estimates that the annual cost of treating tobacco-related diseases will be about $500 billion by 2010 (According to the Journal of Medicine,